GlassScriptPhysician profile
Jay A Shah
NPI 1679736813
$2,805.30
in general payments reported to CMS, 2019-2025
21 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $37.33 · 2021: $104 · 2022: $252 · 2023: $428 · 2024: $269 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $36.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.91 |
| Education | $36.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $592.13 | 2023-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $334.06 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $231.29 | 2022-2025 | Velphoro |
| Amgen INC. | $186.66 | 2019-2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $184.07 | 2025 | |
| Mallinckrodt Enterprises LLC | $177.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $167.43 | 2022-2024 | Farxiga |
| Vantive US Healthcare LLC | $145.17 | 2025 | Renal - Acute |
| Otsuka America Pharmaceutical, INC. | $117.96 | 2019-2025 | Jynarque, Voyxact |
| Scpharmaceuticals INC. | $113.29 | 2025 | |
| Baxter Healthcare | $110.79 | 2021-2023 | Renal - Acute |
| Ardelyx, INC. | $94.44 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $80.36 | 2019-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $79.64 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $41.76 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $37.06 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $30.39 | 2022 | |
| Boston Scientific Corporation | $24.72 | 2025 | Resolution 360 Clip |
| Opko Pharmaceuticals, LLC | $20.11 | 2025 | Rayaldee |
| Glaxosmithkline, LLC. | $18.71 | 2021 | |
| Pfizer INC. | $17.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.